Paris - Delayed Quote EUR

AB Science S.A. (AB.PA)

0.5320 -0.0070 (-1.30%)

As of 3:56:11 PM GMT+1. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

AB Science will hold a web conference on Wednesday, October 14, 2026, from 6:00 p.m. to 7:30 p.m.

GlobeNewswire 21d ago

AB.PA
-1.30%
AB Science today reports its revenues for the first half of 2026 and provides an update on its activities

GlobeNewswire 24d ago

AB.PA
-1.30%
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection

GlobeNewswire 1mo ago

AB.PA
-1.30%
AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026

GlobeNewswire 2mo ago

AB.PA
-1.30%
AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million

GlobeNewswire 2mo ago

AB.PA
-1.30%
AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs

GlobeNewswire 3mo ago

AB.PA
-1.30%
AB
AB Science announces the successful completion of a EUR 2.3 million private placement

GlobeNewswire 4mo ago

AB.PA
-1.30%
AB
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042

GlobeNewswire 4mo ago

AB.PA
-1.30%
AB Science reports its revenues for the year 2025 and provides an update on its activities

GlobeNewswire 5mo ago

AB.PA
-1.30%
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors

GlobeNewswire 6mo ago

AB.PA
-1.30%
AB Science provides an update on its clinical development program.

GlobeNewswire 6mo ago

AB.PA
-1.30%
AB
The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight

PR Newswire 2mo ago

ROP.SW

ANVS

AB.PA
-1.30%

Performance Overview

Return	AB.PA	CAC 40 (^FCHI)
YTD	-65.36%	-1.32%
1-Year	-55.07%	-0.84%
3-Year	-79.46%	+14.11%

U.S. markets close in 5h 10m

AB Science S.A. (AB.PA)

AB Science will hold a web conference on Wednesday, October 14, 2026, from 6:00 p.m. to 7:30 p.m.

AB Science today reports its revenues for the first half of 2026 and provides an update on its activities

AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection

AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026

AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million

AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs

AB Science announces the successful completion of a EUR 2.3 million private placement

AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042

AB Science reports its revenues for the year 2025 and provides an update on its activities

AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors

AB Science provides an update on its clinical development program.

The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight